All In MedTech

FDA Clearance Tracker · K253316

PhAST instrument and PhAST Blood Culture Gram-negative Panel

A 510(k) clearance means FDA found the device substantially equivalent to one already on the market. It is not an approval, and it is not a finding that the device works better than others.

Last checked: Nov 19, 2026Latest source record: Jun 26, 2026 (this decision)Source: openFDAMethods & limitations

510(k)Breakthrough

Decided

Jun 26, 2026

Substantially Equivalent

Time to decision

269 days

Received Sep 30, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

510(k)

Traditional

Device class

Class II

The decision

FDA number
K253316
Device name
PhAST instrument and PhAST Blood Culture Gram-negative Panel
Applicant
Phast Corp.
Applicant location
Boston, MA
Received
Sep 30, 2025
Decided
Jun 26, 2026
Decision
Substantially Equivalent
Submission type
Traditional

Device type

Device class
Class II
Regulation
21 CFR 866.1650

Every decision under product code SAN

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code SAN. The earliest in FDA's data is K211815, decided Apr 2, 2024.
  • It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).

Source documents

The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.

Other decisions for Phast Corp.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.